Key facts
- This page summarizes Walter Edward Martucci II's Form 4 filing for Akili, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2024, 10:29.
Walter Edward Martucci II - 02 Jul 2024 Form 4 Insider Report for Akili, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 02 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2024, 10:29:48 UTC
- Prior SEC filing
- 06 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jacqueline Studer, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Walter Edward Martucci II filed Form 4 for Akili, Inc. on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 06 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKLI
transaction
Common Stock, par value $0.0001
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -48,690
- Change %
- -33%
- Price
- Shares after
- 99,548
- Date
- 02 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
AKLI
transaction
Common Stock, par value $0.0001
Disposed to Issuer
- Transaction value
- Shares
- -99,548
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Jul 2024
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Walter Edward Martucci II is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time") with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person or his affiliates was converted into the Offer Price.
Footnote F2
Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.
Footnote F3
Reflects disposition of time-based Issuer RSUs pursuant to the terms of the Merger Agreement. Each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into the right to receive a cash payment without interest, less any applicable tax withholding, equal to the Offer Price, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.